The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Abstract
Liver fibrosis and in particular cirrhosis are the major causes of morbidity and mortality of patients with chronic liver disease. Their prevention or reversal have become major endpoints in clinical trials with novel liver specific drugs. Remarkable progress has been made with therapies that efficiently address the cause of the underlying liver disease, as in chronic hepatitis B and C. Highly effective antiviral therapy can prevent progression or even induce reversal in the majority of patients, but such treatment remains elusive for the majority of liver patients with advanced alcoholic or nonalcoholic steatohepatitis, genetic or autoimmune liver diseases. Moreover, drugs that would speed up fibrosis reversal are needed for patients with cirrhosis, since even with effective causal therapy reversal is slow or the disease may further progress. Therefore, highly efficient and specific antifibrotic agents are needed that can address advanced fibrosis, i.e., the detrimental downstream result of all chronic liver diseases. This review discusses targeted antifibrotic therapies that address molecules and mechanisms that are central to fibrogenesis or fibrolysis, including strategies that allow targeting of activated hepatic stellate cells and myofibroblasts and other fibrogenic effector cells. Focus is on collagen synthesis, integrins and cells and mechanisms specific including specific downregulation of TGFbeta signaling, major extracellular matrix (ECM) components, ECM-crosslinking, and ECM-receptors such as integrins and discoidin domain receptors, ECM-crosslinking and methods for targeted delivery of small interfering RNA, antisense oligonucleotides and small molecules to increase potency and reduce side effects. With an increased understanding of the biology of the ECM and liver fibrosis and an improved preclinical validation, the translation of these approaches to the clinic is currently ongoing. Application to patients with liver fibrosis and a personalized treatment is tightly linked to the development of noninvasive biomarkers of fibrosis, fibrogenesis and fibrolysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Discoidin Domain Receptors: Potential Actors and Targets in Cancer
Rammal, H., Saby, C., Magnien, K., Gulick, L. V., Garnotel, R., Buache, É., Btaouri, H. E., Jeannesson, P., & Morjani, H. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00055 · Cited by 133
RetractedHynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Self-citationMarcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061
Targeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Cited by
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification
(2021) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.10.001 · Cited by 851
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Fibroblast and myofibroblast activation in normal tissue repair and fibrosis
Younesi, F. S., Miller, A. E., Barker, T. H., Rossi, F. M. V., & Hinz, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00716-0 · Cited by 681
Farrell, G., Schattenberg, J. M., Leclercq, I., Yeh, M. M., Goldin, R., Teoh, N., & Schuppan, D. (2019) · Hepatology · doi:10.1002/hep.30333 · Cited by 313
“Models That Replicate Liver Fibrosis in NASH As outlined previously, the best preclinical fibrosis models for antifibrotic drug testing include improved standardized models of toxin-induced fibrosis, especially fibrosis reversibility after toxin discontinuation, coupled with models of biliary fibrosis, such as the mul…”
InfluentialSelf-citationPakshir, P., Noskovicova, N., Lodyga, M., Son, D. O., Schuster, R., Goodwin, A., Karvonen, H., & Hinz, B. (2020) · Journal of Cell Science · doi:10.1242/jcs.227900 · Cited by 293
Chen, W., Yang, A., Jia, J., Popov, Y. V., Schuppan, D., & You, H. (2020) · Hepatology · doi:10.1002/hep.31236 · Cited by 284
Self-citationCellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
The Role of Myofibroblasts in Physiological and Pathological Tissue Repair
Schuster, R., Younesi, F., Ezzo, M., & Hinz, B. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041231 · Cited by 232
Mechanical communication in fibrosis progression
Long, Y., Niu, Y., Liang, K., & Du, Y. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.10.002 · Cited by 233
Collagen biology and non‐invasive biomarkers of liver fibrosis
Karsdal, M. A., Daniels, S. J., Holm Nielsen, S., Bager, C., Rasmussen, D. G. K., Loomba, R., Surabattula, R., Villesen, I. F., Luo, Y., Shevell, D., et al. (2020) · Liver International · doi:10.1111/liv.14390 · Cited by 197
Self-citationMechanical regulation of myofibroblast phenoconversion and collagen contraction
Hinz, B., McCulloch, C. A., & Coelho, N. M. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.03.027 · Cited by 182
Implant Fibrosis and the Underappreciated Role of Myofibroblasts in the Foreign Body Reaction
Noskovicova, N., Hinz, B., & Pakshir, P. (2021) · Cells · doi:10.3390/cells10071794 · Cited by 184
ECM formation and degradation during fibrosis, repair, and regeneration
Mayorca-Guiliani, A. E., Leeming, D. J., Henriksen, K., Mortensen, J. H., Nielsen, S. H., Anstee, Q. M., Sanyal, A. J., Karsdal, M. A., & Schuppan, D. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00063-4 · Cited by 176
Self-citationBrunt, E. M., Kleiner, D. E., Wilson, L. A., Sanyal, A. J., Neuschwander‐Tetri, B. A., & for the Nonalcoholic Steatohepatitis Clinical Research Network (2019) · Hepatology · doi:10.1002/hep.30418 · Cited by 154
Multipotent stromal cells: One name, multiple identities
Soliman, H., Theret, M., Scott, W., Hill, L., Underhill, T. M., Hinz, B., & Rossi, F. M. V. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.001 · Cited by 147
Yang, A.-T., Kim, Y.-O., Yan, X.-Z., Abe, H., Aslam, M., Park, K.-S., Zhao, X.-Y., Jia, J.-D., Klein, T., You, H., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.12.005 · Cited by 144
Self-citationLiver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
Critical role of estrogen in the progression of chronic liver diseases
Ezhilarasan, D. (2020) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/j.hbpd.2020.03.011 · Cited by 96
Lee, J., Byun, J., Shim, G., & Oh, Y.-K. (2022) · Nature Communications · doi:10.1038/s41467-022-29186-8 · Cited by 79
Integrins as a drug target in liver fibrosis
Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022) · Liver International · doi:10.1111/liv.15157 · Cited by 74
The Matrisome, Inflammation, and Liver Disease
Dolin, C. E., & Arteel, G. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0039-3402516 · Cited by 38
Crosstalk between NK cells and hepatic stellate cells in liver fibrosis (Review)
Zhang, Y., Wu, Y., Shen, W., Wang, B., & Yuan, X. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12724 · Cited by 35
Insights on drug and gene delivery systems in liver fibrosis
Vyas, K., & Patel, M. M. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100779 · Cited by 30
Chen, W., Sun, Y., Chen, S., Ge, X., Zhang, W., Zhang, N., Wu, X., Song, Z., Han, H., Desert, R., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000423 · Cited by 30
“Despite pharmacological approaches to requiesce activated HSC (aHSCs) and other profibrogenic effector cells, [4,5] there are limited clinical breakthroughs to date.”
Self-citationReversal of established liver fibrosis by IC-2-engineered mesenchymal stem cell sheets
Itaba, N., Kono, Y., Watanabe, K., Yokobata, T., Oka, H., Osaki, M., Kakuta, H., Morimoto, M., & Shiota, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-43298-0 · Cited by 29
Shi, Z., Ren, M., & Rockey, D. C. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00302.2019 · Cited by 27
Sphingosine Kinase 1 Aggravates Liver Fibrosis by Mediating Macrophage Recruitment and Polarization
Ding, X., Zhang, X., Cao, J., Chen, S., Chen, Y., Yuan, K., Chen, B., Yang, G., Li, S., Yang, J., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101406 · Cited by 23
Zhu, D., Sun, Z., Wei, J., Zhang, Y., An, W., Lin, Y., & Li, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s450284 · Cited by 17
Iwasawa, T., Nojiri, S., Tsuchiya, A., Takeuchi, S., Watanabe, T., Ogawa, M., Motegi, S., Sato, T., Kumagai, M., Nakaya, T., et al. (2021) · Regenerative Therapy · doi:10.1016/j.reth.2021.07.002 · Cited by 14
“Production and ho liver damage can lead to fibrosis and cirrhosis [1].”
BackgroundFu, R., Zu, S.-J., Liu, Y.-J., Li, J.-C., Dang, W.-Z., Liao, L.-P., Liu, L.-P., Chen, P.-Y., Huang, H.-M., Wu, K.-H., et al. (2022) · Bioengineered · doi:10.1080/21655979.2022.2066756 · Cited by 12
Shao, C., Xu, H., Sun, X., Pan, Y., Liang, X., Huang, J., He, Y., Guo, W., Ye, L., & Zhang, J. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117486 · Cited by 12
Metadata
- Authors
- Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O.
- Venue
- Matrix Biology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 68-69
- Pages
- 435-451
- ISSN
- 0945-053X (ISSN-L)
- OpenAlex
- W2796699845
- Cited by
- 435
- References
- 156
- FWCI
- 24.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.